IARC Monographs Preamble
38
References 1
Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, et al. (2016). 2
Mutational signatures associated with tobacco smoking in human cancer. Science. 3
354(6312):618–22. https://doi.org/10.1126/science.aag0299 PMID:27811275 4
Axelson O, Steenland K (1988). Indirect methods of assessing the effects of tobacco use in 5
occupational studies. Am J Ind Med. 13(1):105–18. https://doi.org/10.1002/ajim.4700130107 6
PMID:3344750 7
Baan RA, Stewart BW, Straif K, editors (2019). Tumour site concordance and mechanisms of 8
carcinogenesis (IARC Scientific Publication No. 165). Lyon, France: International Agency 9
for Research on Cancer. Available from: http://publications.iarc.fr/578. 10
Bieler GS, Williams RL (1993). Ratio estimates, the delta method, and quantal response tests for 11
increased carcinogenicity. Biometrics. 49(3):793–801. https://doi.org/10.2307/2532200 12
PMID:8241374 13
Capen CC, Dybing E, Rice JM, Wilbourn JD, editors (1999). Species differences in thyroid, 14
kidney and urinary bladder carcinogenesis (IARC Scientific Publication No. 147). Lyon, 15
France: IARC Press. Available from: http://publications.iarc.fr/302 PMID:10627184 16
Chiu WA, Guyton KZ, Martin MT, Reif DM, Rusyn I (2018). Use of high-throughput in vitro 17
toxicity screening data in cancer hazard evaluations by IARC Monograph Working Groups. 18
ALTEX. 35(1):51–64. https://doi.org/10.14573/altex.1703231 PMID:28738424 19
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. (2005). Transparency 20
in IARC Monographs. Lancet Oncol. 6(10):747. https://doi.org/10.1016/S1470-21
2045(05)70380-6 22
Cogliano VJ, Baan RA, Straif K, Grosse Y, Secretan MB, El Ghissassi F, et al. (2004). The 23
science and practice of carcinogen identification and evaluation. Environ Health Perspect. 24
112(13):1269–74. https://doi.org/10.1289/ehp.6950 PMID:15345338 25
Dunson DB, Chen Z, Harry J (2003). A Bayesian approach for joint modeling of cluster size and 26
subunit-specific outcomes. Biometrics. 59(3):521–30. https://doi.org/10.1111/1541-27
0420.00062 PMID:14601753 28
Fung KY, Krewski D, Smythe RT (1996). A comparison of tests for trend with historical controls 29
in carcinogen bioassay. Can J Stat. 24(4):431–54. https://doi.org/10.2307/3315326 30
Garcia-Closas M, Vermeulen R, Cox D, Lan Q, Caporaso N, Hunter D, et al. (2011). Population-31
based study designs in molecular epidemiology. In: Rothman N, Hainaut P, Schulte P, Smith 32
M, Boffetta P, Perera FP, editors. Molecular epidemiology: principles and practices. Lyon, 33
France: International Agency for Research on Cancer; pp. 241–59. 34
García-Closas M, Vermeulen R, Sherman ME, Moore LE, Smith MT, Rothman N (2006). 35
Application of biomarkers in cancer epidemiology. In: Schottenfeld D, Fraumeni JF Jr, 36
editors. Cancer epidemiology and prevention. 3rd ed. New York (NY), USA: Oxford 37
University Press; pp. 70–88. https://doi.org/10.1093/acprof:oso/9780195149616.003.0006 38
Gart JJ, Krewski D, Lee PN, Tarone RE, Wahrendorf J (1986). Statistical methods in cancer 39
research, Volume III: The design and analysis of long-term animal experiments (IARC 40
Scientific Publication No. 79). Lyon, France: International Agency for Research on Cancer. 41
Greenland S, O’Rourke K (2008). Meta-analysis. In: Rothman KJ, Greenland S, Lash TL, 42
editors. Modern epidemiology. 3rd ed. Philadelphia (PA), USA: Wolters Kluwer 43
Health/Lippincott Williams & Wilkins; pp. 652–682. 44
Greim H, Gelbke H-P, Reuter U, Thielmann HW, Edler L (2003). Evaluation of historical control 45
data in carcinogenicity studies. Hum Exp Toxicol. 22(10):541–9. 46
https://doi.org/10.1191/0960327103ht394oa PMID:14655720 47